Results 141 to 150 of about 131,479 (353)

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source

Impact of evidence-based nursing interventions on psychological status and myocardial injury in patients with myocardial infarction following percutaneous coronary intervention for reperfusion injury

Frontiers in Physiology
ObjectivePercutaneous coronary intervention for myocardial infarction can cause reperfusion injury with both physical and psychological impacts on patients.
Ni Li, Xi Chen
doaj   +1 more source

Announcement: Spotlight on Reducing the Impact of Myocardial Ischaemia/Reperfusion Injury [PDF]

, 2011

openalex   +1 more source

Cardioprotective effects of exogenous and endogenous hydrocortisone in the rabbit model of ischemia-reperfusion Efectos cardioprotectores de la hidrocortisona exógena y endógena en el modelo isquemia-reperfusión de conejo [PDF]

, 2010
Reducing the infarct size in acute myocardial infarction is one of the most important goals driving new drug research and development. During the last two decades, many clinical studies have found cardioprotective effects of corticosteroids, but their ...
Davarian, A., Khori, V., Nayebpour, M.
core  

Cardiogenic shock mortality according to Aetiology in a Mediterranean cohort: Results from the Shock‐CAT study

ESC Heart Failure, Volume 12, Issue 2, Page 1336-1345, April 2025.
Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García, Teresa López‐Sobrino, Esther Sanz‐Girgas, Maria R. Cueto, Jaime Aboal, Pablo Pastor, Irene Buera, Alessandro Sionis, Rut Andrea, Judit Rodríguez‐López, Jose Carlos Sánchez‐Salado, Carlos Tomas, Jordi Bañeras, Albert Ariza, Josep Lupón, Antoni Bayés‐Genís, Ferran Rueda, Grup de Treball de Cures Agudes Cardiològiques Societat Catalana de Cardiologia   +17 more
wiley   +1 more source

The roles of Th cells in myocardial infarction

Cell Death Discovery
Myocardial infarction, commonly known as a heart attack, is a serious condition caused by the abrupt stoppage of blood flow to a part of the heart, leading to tissue damage.
Jun Liu, Feila Liu, Tingting Liang, Yue Zhou, Xiaohan Su, Xue Li, Jiao Zeng, Peng Qu, Yali Wang, Fuli Chen, Qian Lei, Gang Li, Panke Cheng   +12 more
doaj   +1 more source

Sevoflurane attenuates cardiomyocyte apoptosis by mediating the miR-219a/AIM2/TLR4/MyD88 axis in myocardial ischemia/reperfusion injury in mice [PDF]

, 2020
Yan Li, Na Xing, Jingjing Yuan, Jianjun Yang   +3 more
openalex   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

ESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen, Jiahao Shi, Yue Wu, Lizhu Miao, Zilin Wang, Yixuan Wang, Siwei Xu, Yu Lou   +7 more
wiley   +1 more source

Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide [PDF]

, 2001
Background: The sulfonylurea glibenclamide (Glib) abolishes the cardioprotective effect of ischemic preconditioning (IP), presumably by inhibiting mitochondrial KATP channel opening in myocytes. Glimepiride (Glim) is a new sulfonylurea reported to affect
Baxter, G.F., Lawrence, C.L., Maddock, H.L., Mocanu, M.M., Standen, N.B., Yellon, D.M.   +5 more
core  

Cuproptosis‐Related Genes in Immune Infiltration and Diagnosis in Hepatitis B Virus‐Related Acute Liver Failure

Exploration, EarlyView.
The role of cuproptosis in HBV‐ALF was explored via bioinformatics and liver biopsy tissues. There are some crosstalks among cuproptosis, immune infiltration, and ferroptosis (The figure was created by Bio Render). ABSTRACT Hepatitis B virus (HBV) infection poses a significant challenge to global health, particularly in developing countries such as ...
Jingwen Deng, Tao Zhu, Yueyang Wang, Sitong Zhang, Hong Deng, Guilan Quan, Tingting Peng, Chuanbin Wu, Huiqiang Cai, Chao Lu, Xiaopeng Cai   +10 more
wiley   +1 more source